Multiphasic 68Ga-PSMA PET/CT in the detection of early recurrence in prostate cancer patients with a PSA Level of Less Than 1 ng/mL: A prospective study of 135 patients

By Beheshti M, Manafi-Farid R, Geinitz H, et al
Published October 1, 2020

Key Takeaways

A prospective study was conducted to ascertain the effect of the multiphasic acquisition of 68Ga-PSMA PET/CT in the detection of recurrent prostate cancer in the early stage of biochemical recurrence with a prostate-specific antigen (PSA) level of less than 1 ng/mL. Researchers performed a prospective monocentric study on 135 prostate cancer patients with biochemical recurrence and a PSA level of less than 1 ng/mL. The results exhibited that in patients with a PSA level of 0.5–1.0 ng/mL, 68Ga-PSMA PET/CT showed promise for early detection of recurrent disease. Nevertheless, it displayed limited value in patients with a PSA level of less than 0.5 ng/mL. It was reported that multiphasic 68Ga-PSMA PET/CT led to a better determination of equivocal findings. Delayed acquisitions seem to have a greater impact on clarifying equivocal findings, although dynamic images may provide helpful information for the assessment of the prostate bed.

Read the full article on The Journal of Nuclear Medicine.

Share with emailShare to FacebookShare to LinkedInShare to Twitter